Loading…
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Shandra Eisenga Human Cell and Tissue Product Safety Act
Client: INTERNATIONAL SOCIETY FOR STEM CELL RESEARCH · Firm: INTERNATIONAL SOCIETY FOR STEM CELL RESEARCH
HR 1082, Shandra Eisenga Human Cell and Tissue Product Safety Act HR 5304, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026
Shandra Eisenga Human Cell and Tissue Product Safety Act
Client: INTERNATIONAL SOCIETY FOR STEM CELL RESEARCH · Firm: INTERNATIONAL SOCIETY FOR STEM CELL RESEARCH
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
INTERNATIONAL SOCIETY FOR STEM CELL RESEARCH via INTERNATIONAL SOCIETY FOR STEM CELL RESEARCH
2025 · fourth_quarter · Q4
FY26 Labor-HHS appropriations, research with human fetal tissue
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INTERNATIONAL SOCIETY FOR STEM CELL RESEARCH via INTERNATIONAL SOCIETY FOR STEM CELL RESEARCH
2025 · third_quarter · Q3
Source: Senate LDA
HR 1082, Shandra Eisenga Human Cell and Tissue Product Safety Act
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026
Client: INTERNATIONAL SOCIETY FOR STEM CELL RESEARCH · Firm: INTERNATIONAL SOCIETY FOR STEM CELL RESEARCH
HR 1082, Shandra Eisenga Human Cell and Tissue Product Safety Act HR 5304, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026
Accelerating Kids’ Access to Care Act
Client: INTERNATIONAL SOCIETY FOR STEM CELL RESEARCH · Firm: INTERNATIONAL SOCIETY FOR STEM CELL RESEARCH
HR 7188 / S 3733, Shandra Eisenga Human Cell and Tissue Products Safety Act HR 4758 / S 2372, Accelerating Kids Access to Care Act
Shandra Eisenga Human Cell and Tissue Product Safety Act
Client: INTERNATIONAL SOCIETY FOR STEM CELL RESEARCH · Firm: INTERNATIONAL SOCIETY FOR STEM CELL RESEARCH
HR 7188 / S 3733, Shandra Eisenga Human Cell and Tissue Products Safety Act HR 4758 / S 2372, Accelerating Kids Access to Care Act
Shandra Eisenga Human Cell and Tissue Product Safety Act
Client: INTERNATIONAL SOCIETY FOR STEM CELL RESEARCH · Firm: INTERNATIONAL SOCIETY FOR STEM CELL RESEARCH
HR 7188, Shandra Eisenga Human Cell and Tissue Products Safety Act House FY25 Labor-HHS appropriations bill House FY25 FSGG appropriations bill Senate FY25 FSGG appropriations bill
Shandra Eisenga Human Cell and Tissue Product Safety Act
Client: INTERNATIONAL SOCIETY FOR STEM CELL RESEARCH · Firm: INTERNATIONAL SOCIETY FOR STEM CELL RESEARCH
HR 7188 / S 3733, Shandra Eisenga Human Cell and Tissue Products Safety Act
Accelerating Kids’ Access to Care Act
Client: INTERNATIONAL SOCIETY FOR STEM CELL RESEARCH · Firm: INTERNATIONAL SOCIETY FOR STEM CELL RESEARCH
HR 7188 / S 3733, Shandra Eisenga Human Cell and Tissue Products Safety Act HR 4758 / S 2372, Accelerating Kids Access to Care Act
Shandra Eisenga Human Cell and Tissue Product Safety Act
Client: INTERNATIONAL SOCIETY FOR STEM CELL RESEARCH · Firm: INTERNATIONAL SOCIETY FOR STEM CELL RESEARCH
HR 7188 / S 3733, Shandra Eisenga Human Cell and Tissue Products Safety Act HR 4758 / S 2372, Accelerating Kids Access to Care Act
Shandra Eisenga Human Cell and Tissue Product Safety Act
Client: INTERNATIONAL SOCIETY FOR STEM CELL RESEARCH · Firm: INTERNATIONAL SOCIETY FOR STEM CELL RESEARCH
HR 7188 / S 3733, Shandra Eisenga Human Cell and Tissue Products Safety Act
Safe RESEARCH Act
Client: INTERNATIONAL SOCIETY FOR STEM CELL RESEARCH · Firm: INTERNATIONAL SOCIETY FOR STEM CELL RESEARCH
H.R. 398, Protecting Life and Integrity in Research Act; H.R. 416, Prohibiting Abortion Industry's Lucrative Loophole Act; H.R. 1466, Safe RESEARCH Act; S. 751, Human-Animal Chimera Prohibition Act; chimeric embryo research; fetal tissue research; validating a test for prion diseases; unproven cellular therapies
Protecting Life and Integrity in Research Act of 2023
Client: INTERNATIONAL SOCIETY FOR STEM CELL RESEARCH · Firm: INTERNATIONAL SOCIETY FOR STEM CELL RESEARCH
H.R. 398, Protecting Life and Integrity in Research Act; H.R. 416, Prohibiting Abortion Industry's Lucrative Loophole Act; H.R. 1466, Safe RESEARCH Act; S. 751, Human-Animal Chimera Prohibition Act; chimeric embryo research; fetal tissue research; validating a test for prion diseases; unproven cellular therapies
Prohibiting Abortion Industry’s Lucrative Loopholes Act
Client: INTERNATIONAL SOCIETY FOR STEM CELL RESEARCH · Firm: INTERNATIONAL SOCIETY FOR STEM CELL RESEARCH
H.R. 398, Protecting Life and Integrity in Research Act; H.R. 416, Prohibiting Abortion Industry's Lucrative Loophole Act; H.R. 1466, Safe RESEARCH Act; S. 751, Human-Animal Chimera Prohibition Act; chimeric embryo research; fetal tissue research; validating a test for prion diseases; unproven cellular therapies
Human-Animal Chimera Prohibition Act of 2023
Client: INTERNATIONAL SOCIETY FOR STEM CELL RESEARCH · Firm: INTERNATIONAL SOCIETY FOR STEM CELL RESEARCH
H.R. 398, Protecting Life and Integrity in Research Act; H.R. 416, Prohibiting Abortion Industry's Lucrative Loophole Act; H.R. 1466, Safe RESEARCH Act; S. 751, Human-Animal Chimera Prohibition Act; chimeric embryo research; fetal tissue research; validating a test for prion diseases; unproven cellular therapies
HR 1082, Shandra Eisenga Human Cell and Tissue Product Safety Act HR 5304, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INTERNATIONAL SOCIETY FOR STEM CELL RESEARCH via INTERNATIONAL SOCIETY FOR STEM CELL RESEARCH
2025 · second_quarter · Q2
HR 1082, Shandra Eisenga Human Cell and Tissue Product Safety Act
Filing targets: HOUSE OF REPRESENTATIVES
INTERNATIONAL SOCIETY FOR STEM CELL RESEARCH via INTERNATIONAL SOCIETY FOR STEM CELL RESEARCH
2024 · fourth_quarter · Q4
HR 7188 / S 3733, Shandra Eisenga Human Cell and Tissue Products Safety Act
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
INTERNATIONAL SOCIETY FOR STEM CELL RESEARCH via INTERNATIONAL SOCIETY FOR STEM CELL RESEARCH
2024 · third_quarter · Q3
HR 7188 / S 3733, Shandra Eisenga Human Cell and Tissue Products Safety Act HR 4758 / S 2372, Accelerating Kids Access to Care Act
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
INTERNATIONAL SOCIETY FOR STEM CELL RESEARCH via INTERNATIONAL SOCIETY FOR STEM CELL RESEARCH
2024 · second_quarter · Q2
HR 7188, Shandra Eisenga Human Cell and Tissue Products Safety Act House FY25 Labor-HHS appropriations bill House FY25 FSGG appropriations bill Senate FY25 FSGG appropriations bill
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
INTERNATIONAL SOCIETY FOR STEM CELL RESEARCH via INTERNATIONAL SOCIETY FOR STEM CELL RESEARCH
2024 · first_quarter · Q1
FY 24 appropriations (opposing a fetal tissue research policy rider); FY 25 appropriations (seeking support for a GAO report on unproven cellular therapies, advocating for funding for the National Institutes of Health).
INTERNATIONAL SOCIETY FOR STEM CELL RESEARCH via INTERNATIONAL SOCIETY FOR STEM CELL RESEARCH
2023 · fourth_quarter · Q4
Manufacturing of cell and gene therapies; creating an Accelerated Medicines Project cell-based therapy consortium to focus on addressing challenges in the scaling up and out of pluripotent stem cell-based therapies.
Filing targets: Food & Drug Administration (FDA), Natl Institutes of Health (NIH)
INTERNATIONAL SOCIETY FOR STEM CELL RESEARCH via INTERNATIONAL SOCIETY FOR STEM CELL RESEARCH
2023 · third_quarter · Q3
Funding for the National Institutes of Health; restrictions to research with human fetal tissue; curbing the marketing of unproven cellular therapies.
Filing targets: HOUSE OF REPRESENTATIVES
INTERNATIONAL SOCIETY FOR STEM CELL RESEARCH via INTERNATIONAL SOCIETY FOR STEM CELL RESEARCH
2023 · second_quarter · Q2
Funding for the National Institutes of Health; restrictions to research with human fetal tissue; curbing the marketing of unproven cellular therapies.
Filing targets: HOUSE OF REPRESENTATIVES
INTERNATIONAL SOCIETY FOR STEM CELL RESEARCH via INTERNATIONAL SOCIETY FOR STEM CELL RESEARCH
2023 · first_quarter · Q1
H.R. 398, Protecting Life and Integrity in Research Act; H.R. 416, Prohibiting Abortion Industry's Lucrative Loophole Act; H.R. 1466, Safe RESEARCH Act; S. 751, Human-Animal Chimera Prohibition Act; chimeric embryo research; fetal tissue research; validating a test for prion diseases; unproven cellular therapies
Funding for the National Institutes of Health
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
INTERNATIONAL SOCIETY FOR STEM CELL RESEARCH via INTERNATIONAL SOCIETY FOR STEM CELL RESEARCH
2022 · fourth_quarter · Q4
Unproven cellular therapies; prion diseases.
Regenerative medicine, stem cell research, cell therapy manufacturing, prion diseases.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH)
INTERNATIONAL SOCIETY FOR STEM CELL RESEARCH via INTERNATIONAL SOCIETY FOR STEM CELL RESEARCH
2022 · third_quarter · Q3
Stem cell research.
Unproven cellular therapies. Prion diseases.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INTERNATIONAL SOCIETY FOR STEM CELL RESEARCH via INTERNATIONAL SOCIETY FOR STEM CELL RESEARCH
2022 · second_quarter · Q2
Unproven cellular therapies. Prion diseases.
Filing targets: HOUSE OF REPRESENTATIVES
INTERNATIONAL SOCIETY FOR STEM CELL RESEARCH via INTERNATIONAL SOCIETY FOR STEM CELL RESEARCH
2022 · second_quarter · RA
Funding for biomedical research.